Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery disease_ELITE Trial
Phase of Trial: Phase IV
Latest Information Update: 09 Aug 2019
Price : $35 *
At a glance
- Drugs Empagliflozin (Primary) ; Sitagliptin
- Indications Coronary artery disease
- Focus Therapeutic Use
- Acronyms ELITE
- 05 Aug 2019 Status changed from recruiting to completed.
- 21 Jun 2018 Planned End Date changed from 30 Jun 2020 to 30 Apr 2021.
- 21 Jun 2018 Planned primary completion date changed from 31 Dec 2019 to 30 Sep 2020.